Amgen Inc. (AMGN)
Amgen's experimental skin disease drug meets main goals in study
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment for a skin condition known as atopic dermatitis.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.
2 Weight-Loss Stocks That Could Rocket Higher This Year
Injections that help folks manage their appetite already generate over $45 billion in annual revenue. Total sales of weight-management drugs are expected to reach $100 billion annually by 2030.
Amgen (AMGN) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Amgen (AMGN) stood at $335.61, denoting a -0.52% change from the preceding trading day.
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
Many healthcare companies are working hard now on developing the next big weight loss drug. Industry veteran Amgen has an exciting treatment that may not require frequent injections.
Where Will Amgen Be in 5 Years?
Amgen's recent acquisition grants it a significant opportunity. The biotech is developing important medicines of its own.
Amgen (AMGN) Stock Dips While Market Gains: Key Facts
Amgen (AMGN) reachead $332.80 at the closing of the latest trading day, reflecting a -0.73% change compared to its last close.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Amgen (AMGN) Rises Higher Than Market: Key Facts
Amgen (AMGN) closed the most recent trading day at $335.26, moving +0.85% from the previous trading session.
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Eli Lilly and Novo Nordisk have been top stocks for investors who are bullish on the weight loss market. However, fellow biotech Amgen could possess more upside given its more modest valuation.
Why Amgen (AMGN) Outpaced the Stock Market Today
Amgen (AMGN) reachead $328.93 at the closing of the latest trading day, reflecting a +0.92% change compared to its last close.
Tango Therapeutics: Amgen Missteps Devalue PRMT5 Candidates Ahead Of Critical Data
Tango Therapeutics, Inc. offers high-risk, high-reward exposure to PRMT5-inhibitor drugs, with two candidates, TNG908 and TNG462, targeting MTAP-deleted cancers, a substantial market opportunity. TNGX stock volatility is influenced by competitors' PRMT5 data, with recent fluctuations driven by Amgen and Mirati's clinical results. Tango's financial stability is supported by >$300M in cash, a Gilead partnership, and a funding runway until 2027, covering key clinical readouts.
